2022 World Conference on Lung Cancer (ePosters)-EP08.02-171. PRO-CTCAE Analysis of Mobocertinib in EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)

EP08.02-171. PRO-CTCAE Analysis of Mobocertinib in EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)

Back to course

Pdf Summary

The study analyzed the use of the PRO-CTCAE (Patient-Reported Outcomes Version of Common Terminology Criteria for Adverse Events) to assess the frequency and severity of adverse events (AEs) reported by patients with EGFR Exon 20 insertion-positive metastatic non-small cell lung cancer (NSCLC) who were treated with mobocertinib. A total of 90 patients were included in the analysis, with a median time on study of 12.5 months.<br /><br />The results showed that the majority of patients reported favorable tolerability with mobocertinib, as indicated by stable or improved symptoms compared to baseline. However, two AEs, diarrhea and dry skin, were reported as more severe in some patients. For symptom severity, 50% of patients reported "none" or "mild" as their worst category for most symptoms except for dry skin and fatigue. For symptom frequency, 50% of patients reported "never" or "rarely" for nausea and vomiting. However, 54% of patients reported "frequently" or "almost constantly" for diarrhea.<br /><br />Additionally, the study assessed health-related quality of life (QoL) using the EORTC-QLQ-C30 scale. Through Cycle 6, 75% of patients reported "stable" or "improved" Global Health/QoL. When comparing baseline and Cycle 2 scores, the majority of patients showed improvement or remained stable in Global Health/QoL and 10 out of 12 symptom questions. However, patients with diarrhea or dry skin reported worsening severity in most cases.<br /><br />Overall, the study concluded that most patients receiving mobocertinib reported favorable tolerability and maintained or improved health-related QoL. However, diarrhea and dry skin were identified as areas for potential management and support in patients undergoing mobocertinib therapy. The PRO-CTCAE proved useful in assessing patient-reported outcomes in this study.

Asset Subtitle

Rosario Garcia

Meta Tag

Speaker Rosario Garcia

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

PRO-CTCAE

adverse events

EGFR Exon 20

mobocertinib

tolerability

symptom severity

symptom frequency

health-related quality of life

diarrhea

dry skin